Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin

Chen Wang,[1,2] Kathy L. McGraw,[2] Amy F. McLemore,[2] Rami Komrokji,[2] Ashley A. Basiorka,[2] Najla Al Ali,[2] Jeffrey E. Lancet,[2] Eric Padron,[2] Olivier Kosmider,[3] Michaela Fontenay,[3] Pierre Fenaux,[4] Alan F. List[2#] and David A. Sallman[2#]

[1]*Department of Internal Medicine, University of South Florida, Morsani College of Medicine, Tampa, FL, USA;* [2]*Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA;* [3]*Service d'Hématologie Biologique, Assistance Publique-Hôpitaux de Paris. Centre-Université de Paris, Hôpital Cochin, Paris, France and* [4]*Groupe Francophone des Myélodysplasies, Hopital Saint Louis, Paris, France*

#*AFL and DAS contributed equally as co-senior authors.*

Correspondence:

DAVID A. SALLMAN - david.sallman@moffitt.org

doi:10.3324/haematol.2021.278855

Supplement table. Patient's characteristics based on treatment

Median (range) or N (%)	All (n = 69)	Lenalidomide (n = 31)	Lenalidomide plus epoetin β (n = 38)	*P**
Demographics				
Age (years)	73 (46-86)	73 (54-79)	74 (46-86)	0.089
Male (%)	48 (69.6)	19 (61.3)	29 (76.3)	0.177
Clinical features				
Hemoglobin (g/dL)	8.1 (6.3-10.0)	7.8 (6.8-9.6)	8.1 (6.3-10.0)	0.064
ANC (/mm^3)	2.1 (0.15-10.06) (n = 67)	2.00 (0.15-10.06) (n = 30)	2.60 (0.40-5.70) (n = 37)	0.695
Platelet (10^3/mm^3)	235 (58-587) (n = 67)	209 (68-494) (n = 30)	242 (58-587) (n = 37)	0.854
Serum EPO > 200 mU/mL (%)	27 (48.2) (n = 56)	12 (n = 29)	15 (n = 27)	0.289
Bone marrow blast > 2% (%)	27 (39.1)	8 (25.8)	19 (50.0)	0.041
Bone marrow erythroblast (%)	28.9 (1.0-79.0) (n = 67)	36.7 (1.0-65.0) (n = 30)	27.0 (4.4-79.0) (n = 37)	0.308
RARS (%)	38 (55.1)	17 (54.8)	21 (55.3)	0.972
Favorable karyotype (%)	59 (86.8) (n = 68)	27 (87.1)	32 (86.5) (n = 37)	1.000
Splicesome mutation				
SF3B1 (%)	52 (75.4)	26 (83.9)	26 (68.4)	0.168
U2AF (%)	0 (0.0)	0 (0.0)	0 (0.0)	1.000
SRSF2 (%)	6 (8.7)	4 (12.9)	2 (5.3)	0.397
ZRSR2 (%)	5 (7.2)	2 (6.5)	3 (7.9)	1.000
Epigenetic mutation				
TET2 (%)	34 (49.3)	14 (45.2)	20 (52.6)	0.537
IDH (%)	2 (2.9)	2 (6.5)	0 (0.0)	0.198
DNMT3A (%)	13 (18.9)	6 (19.4)	7 (18.4)	0.921
ASXL1 (%)	12 (17.4)	8 (25.8)	4 (10.5)	0.119
EZH2 (%)	2 (2.9)	0 (0.0)	2 (5.3)	0.498
Number of mutations	2 (0-6)	2 (1-6)	2 (0-6)	0.515
IPSS low risk (%)	33 (48.5) (n = 68)	16 (51.6)	17 (45.9) (n = 37)	0.641
Biomarker				
ASC specks > median (%)	34 (49.3)	11 (35.5)	23 (60.5)	0.039
Treatment				
Prior responder to recombinant EPO (%)	24 (35.8) (n = 67)	9 (29.0) (n = 31)	15 (41.7) (n = 36)	0.282
Responder (%)	28 (40.6)	7 (22.6)	21 (55.3)	0.006

* Continuous variables were compared by Mann-Whitney test, and categorical variables were compared using Fisher's exact test or chi-square test, as appropriate.

Abbreviations: ANC, absolute neutrophil count; EPO, erythropoietin; RARS, refractory anemia with ring sideroblasts; IPSS, international prognostic score system; ASC, apoptosis-associated speck-like protein containing a CARD.